Rewiring the biology of immune cells to improve outcomes for patients with aggressive cancers.
Our Partners
Our Partners
Our goal is to engineer superior cell therapies for cancer patients.
Our work starts by developing and harnessing the power of unbiased CRISPR-based discovery platforms to identify novel gene targets that can be manipulated in immune cells to drive more therapeutic behaviors.
Our goal is to engineer superior cell therapies for cancer patients.
To this end, we have built a translationally focused research pipeline to push the bounds of cell therapies for relapsed hematological cancers and aggressive solid tumors. Our work starts by developing and harnessing the power of unbiased CRISPR-based discovery platforms to identify novel gene targets that can be manipulated in immune cells to drive more therapeutic behaviors. Once identified, top targets are mechanistically studied to understand how they affect immune cell behavior. These rewired cells are tested as novel cancer therapies in preclinical models and top-performing cell therapies are rigorously evaluated for safety and efficacy with the goal of advancing towards clinical trials.
Our People
We are a closely integrated group of researchers driven by a common goal, to accelerate the discovery of effective cell therapies for cancer patients. As a new lab situated within the highly collaborative Gladstone-UCSF Genomic Immunology Institute, we benefit from exciting partnerships with other labs combined with an agile team-oriented approach to accelerate the trajectory of our work.
News
Media highlights of Carnevale Lab's research.
Stay Updated
Keep up-to-date with the latest research from the Carnevale lab.
Twitter feed is not available at the moment.